Background on OpenAI and its Investments
OpenAI, the developer of ChatGPT, announced on Thursday that it will invest in Red Queen Bio, a startup focused on preventing malicious actors from developing AI-powered biological weapons. OpenAI is the primary investor in Red Queen Bio’s initial funding round of $15 million, according to Hannu Rajaniemi, one of the company’s co-founders.
OpenAI’s Broader Efforts to Mitigate AI Risks
This investment is part of OpenAI’s broader strategy to support emerging companies addressing AI risks. Last month, OpenAI backed Valthos, a New York-based biosecurity software firm. Jason Kwon, OpenAI’s Director of Strategy, stated that the company would consider investing in other startups tackling similar issues.
“We want to increase the overall resilience of the entire ecosystem,” Kwon said in an interview. “One of the best ways to address risk mitigation is through more technology.”
Potential Risks and Benefits of AI in Biological Research
Researchers and security advocates claim that AI technology could soon accelerate drug development or design new vaccines. However, these same capabilities might also enable malicious actors to create novel and potent biological weapons.
Red Queen Bio was established from Helix Nano, a clinical-stage mRNA therapeutics company that has extensively used AI in drug design. Helix Nano also collaborated with OpenAI to develop tests for assessing AI-related biorisks, according to Kwon.
OpenAI Executives’ Involvement in the Investment
OpenAI’s CEO, Sam Altman, and board advisor Nicole Seligman, who had previously invested in Helix Nano, will receive Red Queen Bio shares as part of the deal. Kwon’s indirect investment came through Y Combinator, a Silicon Valley startup incubator, and is valued at less than $2,500, according to OpenAI.
OpenAI executives did not participate in the approval of their investment in Red Queen Bio, a company spokesperson confirmed. The OpenAI compliance officer and conflict-free board members reviewed and approved the investment.
Red Queen Bio’s Approach to Countering AI-Enhanced Biological Threats
Red Queen Bio will leverage AI models and traditional laboratory experiments to uncover new risks and develop defenses. The company’s name originates from a scene in Lewis Carroll’s “Through the Looking-Glass,” according to Rajaniemi.
“It became clear that biological capabilities were advancing faster than we anticipated,” Rajaniemi explained. “We felt the need to start developing defenses.” Other investors in Red Queen Bio include Cerberus Ventures, Fifty Years, and Halcyon Futures.
Key Questions and Answers
- What is OpenAI investing in? OpenAI is investing in Red Queen Bio, a startup focused on preventing the development of AI-powered biological weapons.
- Why is this investment significant? This investment is part of OpenAI’s broader strategy to address AI risks and increase the overall resilience of the technology ecosystem.
- What are the potential risks and benefits of AI in biological research? AI technology could accelerate drug development or design new vaccines, but it might also enable malicious actors to create novel biological weapons.
- How does Red Queen Bio plan to counter these threats? Red Queen Bio will use AI models and traditional laboratory experiments to identify new risks and develop defenses against AI-enhanced biological threats.
